Rozana ki goli daraxonrasib ibtidai trial mein lablabe ke tumour sikorne lagi

Chemotherapy ke saath di gayi rozana ki goli ne 61 mareezon mein se 60 feesad se kuch zyada mein tumour sikore ya khatam kiye, taham doctoron ke mutabiq yeh ilaaj nahin.

Raaye dein

Tarjuma: Thursday AI. Asal tehreer hi record hai. Asal tehreer parhein

A hand holds a bottle of daraxonrasib tablets
Houston ke MD Anderson Cancer Center ke label wali daraxonrasib goliyon ki botal. File photo. — Reuters
Urdu mein suneinRozana ki goli daraxonrasib ibtidai trial mein lablabe ke tumour sikorne lagi3 min · device ki awaz0:00 / 3:10

— Aik ibtidai trial mein rozana ki goli daraxonrasib ne, chemotherapy ke saath lene par, lablabe ke advanced cancer ke 60 feesad se kuch zyada mareezon mein tumour sikor diye ya khatam kar diye, aise nataij jinhein cancer ke khairati idaray dehaiyon ki sab se bari pesh-raft qarar de rahe hain.

61 mareezon mein se taqreeban sab mein tumour barhna ruk gaye, jin mein haal hi mein aise advanced marz ki tashkhees hui thi jo jism ke doosre hisson tak phail chuka tha. Taqreeban 8 feesad, yaani 12 mein se aik mein, CT scan par cancer nazar aana band ho gaya.

Doctor zor dete hain ke yeh ilaaj nahin hai, aur yeh wazeh nahin ke yeh marz ko kitni der tak roke rakh sakta hai. Mareezon ko awsatan derh saal tak dekha gaya, aur baaz mein is dauran cancer wapas nahin aaya. Yeh janne ke liye ke kya koi mukammal sehatyab ho sakta hai aur kitni muddat ke liye, taweel mutaliat darkar hain.

Yeh kyun ahem hai

Lablabe ka cancer ilaaj ke lihaz se nihayat mushkil hai aur Bartania mein aam cancers mein is ki baqa ki sharah sab se kam hai. Chemotherapy tumour ko kuch had tak sikor sakti hai, lekin cancer aksar dobara barh jata hai, aur advanced marz ke beshtar mareez baras nahin, mahine jeete hain.

Cancer Research UK ne is nateeje ko “dehaiyon ki sab se bari pesh-qadmi” qarar diya. Is ke Dr Sam Godfrey ne kaha ke dawa ne un hadafon ko nishana banane ka rasta dhoond liya hai jinhein nishana banana na-mumkin samjha jata tha. Trial mein shareek America ke Memorial Sloan Kettering Cancer Center ke Dr Wungki Park ne kaha ke doctor zyada gehre radd-e-amal dekh rahe hain aur “bimari par qaboo ki muddat taqreeban dugni” ho rahi hai, jo bil-aakhir taweel baqa mein badal sakti hai.

Daraxonrasib aik hadaf par mabni inhibitor hai jo America mein pehle hi manzoor ho chuka hai. Yeh lablabe ke beshtar cancers mein paye jane wale aur tumour ki numu ko hawa dene wale RAS jeenyati tagheeraat se jud kar unhein band kar deti hai. Phephron aur baiza-dani samet darjanon deegar cancers mein bhi aise hi tagheeraat ho sakte hain, is liye yeh dawa doosre mareezon ke kaam bhi aa sakti hai. Godfrey ne kaha ke unhein umeed hai ke ibtidai kamyabi deegar cancers tak phailai ja sakegi. Yeh kaam EORTC–NCI–AACR Symposium 2026 mein pesh kiya ja raha hai.

America mein tamam cancers ka taqreeban 3 feesad lablabe ka cancer hai aur cancer se amwat ka taqreeban 8 feesad, jo salana taqreeban 53,000 jaanein leta hai. Cancer Research UK ke mutabiq Bartania mein har saal taqreeban 11,500 tashkheesein aur taqreeban 10,200 amwat hoti hain.

TT News Desk

News from The Thursday Times' news desk.

More from this desk

The conversation

Comments are open on this story. An editor reads every one before it appears.

No one has said anything yet. Be the first.

Published by Thursday Media International thursday.media